FDA Approves Rituxan-Chemotherapy Combo for Children with a Variety of Blood Cancers

The FDA approval of Rituxan plus chemotherapy is indicated for the treatment of children aged six months to 18 years who have various forms of lymphoma or a form of leukemia.

To wipe childhood cancer off the map, scientists must chart its genomic landscape

Childhood Liver Cancer "Signatures" May Help Predict Response to Chemo

New chemical technology leads to better targeted therapeutics against high-risk leukemia in the lab

Hopes of a new curative treatment for children with neuroblastoma

Scientists are a step closer to finding a low toxicity treatment for childhood leukaemia

Researchers identify an Achilles’ heel in neuroblastoma

To save children with cancer, doctors turn to new weapons

Childhood Cancer Survivors Are at an Increased Risk for Hospitalization Years After Treatment Ends

Novel targeted therapy could be effective treatment option for deadly childhood cancer

Gene That Causes Deadliest Brain Tumor Also Causes Childhood Cancer

Recent Posts

FDA Approves Rituxan-Chemotherapy Combo for Children with a Variety of Blood Cancers

Archive

Search By Tags